// App-Quantinova.ai

e24044 : Cell-free circulating tumour DNA (ctDNA) in the management of patients (pts) with non-biopsiable (Bx) advanced non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • MArina Kushnir

Principal Investigators

  • Carmen Murias

  • Helen Winter

  • Param Bain

  • Christopher Abbosh

  • Dionysis Papadatos

  • Thomas Newsom-Davis

  • Tanya Ahmad

  • Charles Swanton

  • Martin David Forster

  • David Allan Moore

  • Philip Bennett

  • Iris Faull

  • Richard B. Lanman

  • Hendrik-Tobias Arkenau

Medical Centers

  • Sarah Cannon Research Institute, London, United Kingdom

  • Sarah Cannon Research Institute, London, United Kingdom

  • SCRI, London, London, United Kingdom

  • Kings College London, London, United Kingdom

  • NCRI, London, United Kingdom

  • Chelsea and Westminster Hospital, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Sarah Cannon Molecular Diagnostics, London, United Kingdom

  • Guardant Health, Rewdwood City, CA

  • Guardant Health, Rewdwood City, CA

Locations

  • United States

  • United Kingdom

Companies

  • Guardant Health, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved